Argireline (Acetyl hexapeptide-8)
Aliases: Acetyl Hexapeptide-8 · Acetyl Hexapeptide-3
Last verified: 2026-09-23
The short version
A hexapeptide "topical Botox" — relaxes facial mimicry by reducing muscle contractions; reduces wrinkle depth, especially around eyes and forehead. Key fact: Human data are limited: small trials or case-series reports exist, without large randomized studies. Manufacturer trials (Lipotec): 10–30% wrinkle-depth reduction in 4 weeks; independent studies more modest. Status: research chemical. Legal cosmetic ingredient worldwide.
Identity & type
- Molecular type
- peptide
- Origin
- A hexapeptide "topical Botox" — relaxes facial mimicry by reducing muscle contractions; reduces wrinkle depth, especially around eyes and forehead.
Mechanism of action
Mimics the SNAP-25 N-terminus, competitively destabilizing the SNARE complex → reduced acetylcholine release → milder contraction.
not confirmed in humans
Dosing & routes
Official / clinical context
No approved official document exists for Argireline (Acetyl hexapeptide-8). Any protocols mentioned are to be read as information, not as a recommendation.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
Topical serums 2–10% twice daily. A "relaxation" effect on dynamic wrinkles (around the eyes, forehead) within 2–4 weeks; results are subtle versus botox but visible with regular use.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
A "relaxation" effect on dynamic wrinkles (around the eyes, forehead) within 2–4 weeks; results are subtle versus botox but visible with regular use.
Protocol — official vs community
Official / label
Cosmetic ingredient (Acetyl hexapeptide-8): 2–10% in leave-on products, twice-daily application in study protocols.
Duration: Continuous; studies ran 1–4 months.
One of the few cosmetic peptides with published human split-face trials — effects modest (roughly 10–30% wrinkle-depth changes on instrumentation).
Community (anecdotal)
5–10% serum AM/PM on expression lines.
- Cycle:
- Continuous.
- Break:
- None.
Realistic expectation: softened fine lines over months, at a fraction of botulinum toxin effect.
Human evidence
Human data are limited: small trials or case-series reports exist, without large randomized studies. Manufacturer trials (Lipotec): 10–30% wrinkle-depth reduction in 4 weeks; independent studies more modest.
Preclinical evidence
Manufacturer trials (Lipotec): 10–30% wrinkle-depth reduction in 4 weeks; independent studies more modest.
Known risks
- Rare irritation; effect is superficial and reversible.characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Long-term human safety
- Optimal dose and pharmacokinetics
Frequently asked questions
References
Systematic references are being expanded; verify sources directly before any decision.